Meldrum D R, Donnahoo K K
Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado, 80262, USA.
J Surg Res. 1999 Aug;85(2):185-99. doi: 10.1006/jsre.1999.5660.
Recent evidence has implicated proinflammatory mediators such as TNF-alpha in the pathophysiology of ischemia-reperfusion (I/R) injury. Clinically, serum levels of TNF-alpha are increased after myocardial infarction and after cardiopulmonary bypass. Both cardiopulmonary bypass and renal ischemia-reperfusion injury induce a cascade of events leading to cellular damage and organ dysfunction. Tumor necrosis factor (TNF), a potent proinflammatory cytokine, is released from both the heart and the kidney in response to ischemia and reperfusion. TNF released during cardiopulmonary bypass induces glomerular fibrin deposition, cellular infiltration, and vasoconstriction, leading to a reduction in glomerular filtration rate (GFR). The signaling cascade through which renal ischemia-reperfusion induces TNF production is beginning to be elucidated. Oxidants released following reperfusion activate p38 mitogen-activated protein kinase (p38 MAP kinase) and the TNF transcription factor, NFkappaB, leading to subsequent TNF synthesis. In a positive feedback, proinflammatory fashion, binding of TNF to specific TNF membrane receptors can reactivate NFkappaB. This provides a mechanism by which TNF can upregulate its own expression as well as facilitate the expression of other genes pivotal to the inflammatory response. Following its production and release, TNF results in both renal and myocardial apoptosis and dysfunction. An understanding of these mechanisms may allow the adjuvant use of anti-TNF therapeutic strategies in the treatment of renal injury. The purposes of this review are: (1) to evaluate the evidence which indicates that TNF is produced by the heart following cardiopulmonary bypass; (2) to examine the effect of TNF on myocardial performance; (3) to outline the mechanisms by which the kidney produces significant TNF in response to ischemia and reperfusion; (5) to investigate the role of TNF in renal ischemia-reperfusion injury, (6) to describe the mechanisms of TNF-induced renal cell apoptosis, and (7) to suggest potential anti-TNF strategies designed to reduce renal insufficiency following cardiac surgery.
最近的证据表明,促炎介质如肿瘤坏死因子-α(TNF-α)参与了缺血再灌注(I/R)损伤的病理生理过程。临床上,心肌梗死后和体外循环后血清TNF-α水平会升高。体外循环和肾缺血再灌注损伤都会引发一系列导致细胞损伤和器官功能障碍的事件。肿瘤坏死因子(TNF)是一种强效促炎细胞因子,心脏和肾脏在缺血和再灌注时都会释放。体外循环期间释放的TNF会诱导肾小球纤维蛋白沉积、细胞浸润和血管收缩,导致肾小球滤过率(GFR)降低。肾缺血再灌注诱导TNF产生的信号级联反应已开始得到阐明。再灌注后释放的氧化剂激活p38丝裂原活化蛋白激酶(p38 MAP激酶)和TNF转录因子核因子κB(NFκB),导致随后的TNF合成。以正反馈、促炎的方式,TNF与特定的TNF膜受体结合可重新激活NFκB。这提供了一种机制,通过该机制TNF可以上调其自身的表达,并促进其他对炎症反应至关重要的基因的表达。TNF产生并释放后,会导致肾脏和心肌细胞凋亡及功能障碍。了解这些机制可能有助于在肾损伤治疗中辅助使用抗TNF治疗策略。本综述的目的是:(1)评估表明体外循环后心脏产生TNF的证据;(2)研究TNF对心肌功能的影响;(3)概述肾脏在缺血和再灌注时产生大量TNF的机制;(5)研究TNF在肾缺血再灌注损伤中的作用;(6)描述TNF诱导肾细胞凋亡的机制;(7)提出旨在减少心脏手术后肾功能不全的潜在抗TNF策略。